Cancer Treatment Reviews
Volume 28, Issue 4 , Pages 195-214, August 2002

The metabolic syndrome in long-term cancer survivors, and important target for secondary preventive measures

  • Janine Nuver

      Affiliations

    • Department of Medical Oncology, University Hospital Groningen, Groningen, The Netherlands
  • ,
  • Andries J Smit

      Affiliations

    • Department of Internal Medicine, University Hospital Groningen, Groningen, The Netherlands
  • ,
  • Aleida Postma

      Affiliations

    • Department of Pediatric Oncology, University Hospital Groningen, Groningen, The Netherlands
  • ,
  • Dirk Th Sleijfer

      Affiliations

    • Department of Medical Oncology, University Hospital Groningen, Groningen, The Netherlands
  • ,
  • Jourik A Gietema

      Affiliations

    • Department of Medical Oncology, University Hospital Groningen, Groningen, The Netherlands
    • Corresponding Author InformationCorrespondence to: Jourik A. Gietema, Department of Medical Oncology, University Hospital Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands, Tel.: +31-50-3611334; Fax: +31-50-3614862

Abstract 

With increasing numbers of cancer survivors, attention has been drawn to long-term complications of curative cancer treatment, including a range of metabolic disorders. These metabolic disorders often resemble the components of the so-called metabolic syndrome, or syndrome X, which is an important risk factor for the development of cardiovascular disease. The mechanisms behind the development of metabolic disorders in cancer survivors have not been fully elucidated. However, association studies in the general population have demonstrated correlations between the components of the metabolic syndrome on the one hand and hormonal deficiencies, hypomagnesaemia, and endothelial dysfunction on the other. These latter disorders are regularly reported following curative cancer treatment and could, therefore, be important aetiologic factors in the development of the metabolic syndrome in cancer survivors. This review discusses data on the associations between the metabolic syndrome and treatment-related complications in cancer survivors and possibilities for preventive measures.

Keywords:  long-term cancer survivors, metabolic syndrome, syndrome X, hormones, magnesium, endothelial dysfunction

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Grant RUG2000-2177 from the Dutch Cancer Society.

PII: S0305-7372(02)00038-5

Cancer Treatment Reviews
Volume 28, Issue 4 , Pages 195-214, August 2002